Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification of the gene that codes for the σ 2 receptor
Assaf Alon, Hayden R. Schmidt, Michael D. Wood, et al.
Proceedings of the National Academy of Sciences (2017) Vol. 114, Iss. 27, pp. 7160-7165
Open Access | Times Cited: 240

Showing 26-50 of 240 citing articles:

Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders
Tangui Maurice
Expert Opinion on Drug Discovery (2020) Vol. 16, Iss. 4, pp. 373-389
Open Access | Times Cited: 48
Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes
Halley M. Oyer, Christina M. Sanders, Felix J. Kim
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 47
TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death
Chenbo Zeng, Chi-Chang Weng, Mark E. Schneider, et al.
Cell Death Discovery (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 46
The Biological Function of Sigma-2 Receptor/TMEM97 and Its Utility in PET Imaging Studies in Cancer
Chenbo Zeng, Aladdin Riad, Robert H. Mach
Cancers (2020) Vol. 12, Iss. 7, pp. 1877-1877
Open Access | Times Cited: 44
The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinson’s Disease (PD) and Major Depressive Disorder (MDD)
Kai Yang, Changcai Wang, Taolei Sun
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 43
A proteome-wide map of 20(S)-hydroxycholesterol interactors in cell membranes
Yu-Shiuan Cheng, Tianyi Zhang, Xiang Ma, et al.
Nature Chemical Biology (2021) Vol. 17, Iss. 12, pp. 1271-1280
Open Access | Times Cited: 41
Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer’s Disease
Gilbert M. Rishton, Gary C. Look, Zhi‐Jie Ni, et al.
ACS Medicinal Chemistry Letters (2021) Vol. 12, Iss. 9, pp. 1389-1395
Open Access | Times Cited: 33
Photoaffinity labeling approaches to elucidate lipid–protein interactions
Weizhi Yu, Jeremy M. Baskin
Current Opinion in Chemical Biology (2022) Vol. 69, pp. 102173-102173
Open Access | Times Cited: 27
From Cell to Symptoms: The Role of SARS-CoV-2 Cytopathic Effects in the Pathogenesis of COVID-19 and Long COVID
Pablo Gonzalez-Garcia, Ornella Fiorillo‐Moreno, Eloína Zarate Peñata, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 8290-8290
Open Access | Times Cited: 16
Sigma-1 receptor agonist properties that mediate the fast-onset antidepressant effect of hypidone hydrochloride (YL-0919)
Peng Ren, Jingya Wang, Honglei Chen, et al.
European Journal of Pharmacology (2023) Vol. 946, pp. 175647-175647
Closed Access | Times Cited: 14
Highly specific σ 2 R/TMEM97 ligand FEM-1689 alleviates neuropathic pain and inhibits the integrated stress response
Muhammad Saad Yousuf, James J. Sahn, Hongfen Yang, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 52
Open Access | Times Cited: 13
Skin single-cell transcriptomics reveals a core of sebaceous gland-relevant genes shared by mice and humans
Torsten Thalheim, Marlon R. Schneider
BMC Genomics (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 5
Sigma Receptor (σR) Ligands with Antiproliferative and Anticancer Activity
Markos‐Orestis Georgiadis, Olga Karoutzou, Angeliki‐Sofia Foscolos, et al.
Molecules (2017) Vol. 22, Iss. 9, pp. 1408-1408
Open Access | Times Cited: 41
Sigma-2 Receptor: Past, Present and Perspectives on Multiple Therapeutic Exploitations
Carmen Abate, Mauro Niso, Francesco Berardi
Future Medicinal Chemistry (2018) Vol. 10, Iss. 16, pp. 1997-2018
Closed Access | Times Cited: 40
Small molecule modulators of σ2R/Tmem97 reduce alcohol withdrawal-induced behaviors
Luisa L. Scott, James J. Sahn, Antonio Ferragud, et al.
Neuropsychopharmacology (2018) Vol. 43, Iss. 9, pp. 1867-1875
Open Access | Times Cited: 39
Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo
Sebastiano Intagliata, Abhisheak Sharma, Tamara I. King, et al.
The AAPS Journal (2020) Vol. 22, Iss. 5
Closed Access | Times Cited: 39
Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain
James Michael Brimson, Sirikalaya Brimson, Chanichon Chomchoei, et al.
Expert Opinion on Therapeutic Targets (2020) Vol. 24, Iss. 10, pp. 1009-1028
Closed Access | Times Cited: 38
Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain
Thomas J. Cirino, Shainnel O. Eans, Jéssica Medina, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 36
Sigma-2 Receptor—A Potential Target for Cancer/Alzheimer’s Disease Treatment via Its Regulation of Cholesterol Homeostasis
Kai Yang, Cheng Zeng, Changcai Wang, et al.
Molecules (2020) Vol. 25, Iss. 22, pp. 5439-5439
Open Access | Times Cited: 35
Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration
Giuseppe Felice Mangiatordi, Francesca Intranuovo, Pietro Delre, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 23, pp. 14448-14469
Closed Access | Times Cited: 34
1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design
Faheem Faheem, Banoth Karan Kumar, Kondapalli Venkata Gowri Chandra Sekhar, et al.
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 10, pp. 1119-1147
Closed Access | Times Cited: 32
Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein
Colleen S. Limegrover, Raymond Yurko, Nicholas J. Izzo, et al.
Journal of Neuroscience Research (2021) Vol. 99, Iss. 4, pp. 1161-1176
Open Access | Times Cited: 29
Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer
Joyeeta Roy, Armita Kyani, Maha Hanafi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1990-2019
Closed Access | Times Cited: 12
HDAC/σ1R Dual-Ligand as a Targeted Melanoma Therapeutic
Claudia Giovanna Leotta, Carla Barbaraci, Jole Fiorito, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 179-179
Open Access
Neuroprotective effects of SGLT2 inhibitors empagliflozin and dapagliflozin on Aβ 1–42 -induced neurotoxicity and neuroinflammation in cellular models of Alzheimer's disease
Mehdi Alami, Echarki Zerif, Abdelouahed Khalil, et al.
Journal of Alzheimer s Disease (2025)
Closed Access

Scroll to top